TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of any ethnic group aged between 18 and 65 years~* HIV-positive patients with malignant diseases of the blood (NHL, Hodgkin disease, plasmocytoma, acute and chronic leukaemia) who failed to achieve complete remission (CR) after standard-dose first-line chemotherapy or had a chemosensitive relapse after an initial CR~* Patients must receive HAART~Exclusion Criteria:~* Any of the following conditions:~  * congestive heart failure (NYHA \> II)~ * documented EBV, HBV or HCV infection (only for allogeneic PBSCT)~ * creatinine clearance \< 60 ml/min~ * left ventricular ejection fraction \< 40%~ * bilirubin \> 2 mg/dl~* Severe opportunistic infection~* More than 10% of bone marrow involved with lymphoma~* Between 2 and 5 10\^6 autologous CD34+ cells/kg BW obtained after leukapheresis and CD34 enrichment~* Women of child.bearing potential not under adequate contraceptive protection~* Women who are pregnant or breast feeding~* Known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study~* Participation in another study with an investigational product within less than one month prior to this study~* Simultaneous participation in a study with an investigational drug~* Presence of any disease likely to require procedures altering the schedule of the protocol~* Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator~* Patients with limited mental capacity to the extent that he/she cannot provide informed consent or information regarding adverse events of the study medication~* Patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular disease~* Patients who have previously been admitted to this study~* Patients who will not accept transfusions of blood products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 years and older;~* Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;~* Previously untreated;~* ECOG 0-2~* Adequate renal and hepatic functions;~* Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;~* Signed informed consent~Exclusion Criteria:~* CNS involvement by lymphoma;~* Hypersensitivity to study drugs;~* Active infection;~* Prior treatment with monoclonal antibodies for cancer;~* History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented breast cancer~* Clinical evidence of mets to the liver~* Performance status of 0-2~* Life expectancy of greater equal to 3 months~* Not pregnant~* 4 weeks or more since last radiation therapy~* Recovered from all side effects of prior chemotherapy~* Not needing concurrent chemotherapy~* recovered laboratory values~* Bilirubin \< 2.0~Exclusion Criteria:~* Candidate for surgical resection or ablation of liver lesion/s~* Prior radiation therapy to the liver~* Co-Morbid disease~* pulmonary insufficiency~* Portal vein thrombosis~* Contraindications to angiography~* \> 20 % lung shunting on MAA~* Diffuse extra-hepatic disease~* Concurrent chemotherapy OR capecitabine with 8 weeks~* Failed MAA~* Uncontrolled active infection~* Severe liver dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): All patients will be treated with SIR-Sphere therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years of age and younger than 65 years of age,~* Patient received an obesity-surgery (gastric bypass or sleeve gastrectomy)~* Contribution of muscular weight higher than 15% of the total weight loss after the third month post-surgery.~* Patient that be able to increase their physical activity~* Patient that give their informed consent before any procedure for the study~* Patient affiliated with a health insurance scheme~Exclusion Criteria:~* Patients allergic to one of the supplement's compound.~* Patients with glucocorticoid therapy~* Patients with hyperthyroidism~* Patients commencing insulin treatment or growth hormone~* Protein powder intake (as nutritional complement or as anabolic substance for muscle building practice)~* Oral nutritional supplement intake for malnutrition~* Bone fracture since the surgery~* Infection can cause hypercatabolism (like microbial outbreak or chronic gastric fistula)~* Hospitalization for more than 24 hours since the surgery~* Known physical handicap~* Inability to increase physical activity during 3 months after beginning of the supplementation~* Enteral or parenteral nutrition~* Patients over 158 kg (DEXA impossible)~* Protected adults (guardianship by court order)~* Pregnant woman or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Leucine-enriched amino acid : 2.16g/day (Type: EXPERIMENTAL): Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
- Leucine-enriched amino acid : 4g/day (Type: EXPERIMENTAL): Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Injection Pressure & Adductor Canal Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Planned general anesthetic.~2. American Society of Anesthesia classes I, II, or III.~3. Patients aged 18-65.~4. English-speaking patients.~Exclusion criteria:~1. ASA classes IV and V.~2. Patients younger than 18 or older than 65.~3. Contraindication to regional anesthesia (coagulopathy, patient refusal).~4. Allergy to local anesthetic or other study medications.~5. BMI \> 35 kg/m2.~6. Chronic opioid use (daily or almost daily use for \> 3 months).~7. Active illicit drug use.~8. Additional surgical site other than the limb for adductor canal block.~9. Pregnancy.~10. Preexisting neuropathy in the operative limb.~11. Inability to communicate to investigators or hospital staff.~12. Inability to speak or understand English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- High Pressure (Type: EXPERIMENTAL): High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
- Low Pressure (Type: ACTIVE_COMPARATOR): Low pressure injection of Ropivacaine local anesthetic at less than 15 psi

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docusate/Senna for the Treatment of Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 years, male and non-pregnant, non-lactating females~* Diagnosis of type 1 or type 2 diabetes mellitus~* Clinical diagnosis of diabetic gastroparesis~Exclusion Criteria:~* Diagnosed idiopathic gastroparesis~* A history or inflammatory bowel disease, such as Crohn's disease or ulcerative colitis~* A history of bowel obstruction, current unexplained abdominal pain, or undiagnosed rectal bleeding~* Gastrointestinal cancer~* Any active cancer~* Prior gastric surgery~* End-stage heart disease, liver disease, lung disease~* Known or suspected drug abuse~* Any condition requiring use of daily narcotics~* Concurrent usage of mineral oil or products containing mineral oil~* Current or recent (within the last 3 months) usage of Senokot-S, docusate or senna

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose (Type: EXPERIMENTAL): 8.6/50 mg of senna/docusate, oral, twice daily
- Low-dose (Type: EXPERIMENTAL): 8.6/50 mg of senna/docusate, oral, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Major Inclusion Criteria:~1. Chronic heart failure patients, hospitalized due to decompensated heart failure (ADHF) with NYHA Class III-IV symptoms (ADHF is defined by the presence of at least one of the following symptoms/signs: dyspnea w/orthopnea, jugular venous distension, peripheral edema +2, abdominal ascites, signs of CHF on chest X-Ray)~2. LVEF ≤ 40 % within the past 3 months~Major Exclusion Criteria:~1. Acute Q-wave myocardial infarction or Acute coronary syndrome within past 30 days~2. Cardiac surgery within the past 30 days~3. Implantation of cardiac resynchronization device within past 30 days or a possibility of implanting a biventricular pacer within 90 days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Criteria relating to the population studied: patients aged 18 to 65 years old, men or women, regardless of ethnic origin.~* Nosological criteria: HIV-1 infection, documented by a complete western blot and/or a detectable viral load at the time of diagnosis, regardless of the viral subtype.~* Pathology severity and progression criteria: patients with a CD4+ count greater than 500 elements/mm3 at the last follow-up visit prior to inclusion in the study. Undetectable viral load for at least six months on stable treatment.~* Criteria relating to treatments/strategies/procedures: Current cART treatment mandatory, regardless of the combination of anti-retrovirals, effective with undetectable viral load. The number of processing lines is not limited.~* Criteria relating to regulation: Absence of opposition~Exclusion Criteria:~* Criteria relating to the population studied: pregnant or breastfeeding women~* Criteria relating to contraindications to the protocol explorations:~Acute or chronic anaemias Acute infections, fever Coagulation disorders, patients taking anticoagulants~- Criteria relating to regulation: Subjects placed under judicial safeguard, guardianship or curatorship Subjects participating in another research with an ongoing exclusion period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Adult patients infected by HIV, controlled under treatment. (Type: EXPERIMENTAL): Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Can Objective Compliance Monitoring Increase Mandibular Advancement Device Usage in Obstructive Sleep Apnea Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* obstructive sleep apnea patients without a history of soft palate surgery and moderate to severe periodontal disease.~Exclusion Criteria:~* central sleep apnea~* active mandibular disease~* tooth grinding~* moderate to severe periodontal disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MAD for subjective compliance (Type: ACTIVE_COMPARATOR): MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
- MAD for objective compliance (Type: EXPERIMENTAL): MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vioxx and Radiation Therapy for Brainstem Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed infiltrating lesion involving the pons and an MRI pattern of diffuse infiltration, that is not focal. The tumor may extend beyond the boundary of the pons.~* MRI of the brain with or without gadolinium within 4 weeks of starting therapy.~* Clinical history \< 6 months duration~* Children \>3 years of age and adults \>18 years of age~* Treatment to begin within 6 weeks of diagnosis.~* Written informed consent~* Performance status: ECOG 0,1,2 or equivalent Lansky Play Performance Scale.~* All patients must have adequate bone marrow function (ANC\>1000, platelets \>100,000, SGPT \< 2.5x ULN) and renal function (creatinine clearance \>50/ml/min/1.73 m2 or age-adjusted serum creatinine \< 3x ULN)~  * MRI of the spine within 4 weeks of starting therapy.~Exclusion Criteria:~* Pregnancy. All participants who are of child-bearing age must agree to use a method of birth control/pregnancy prevention.~* Bilirubin \> 3x ULN.~* History of gastrointestinal bleeding.~* History of GI perforation due to ulcerative disease.~* Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)~* Prior therapy (Dexamethasone is not considered therapy.)~* Prior malignancy~* Metastasis to the spine.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vioxx MTD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects or postmenopausal female subjects aged between 19-70 years~* High risk patients (PROCAM risk ≥20%) on a stable statin-therapy, but at least simvastatin 20 mg/d~* HDL-cholesterol ≤50 mg/dl and /or triglycerides 150-400 mg/dl and/or LDL-cholesterol 70 - 150 mg/dl~* Lipoprotein (a) \< 30 mg/dl~* Patients may have normal glucose metabolism (normal HOMA), be insulin resistant (abnormal HOMA), have impaired fasting glucose or impaired glucose tolerance but not diabetes mellitus.~* Without niacin therapy for at least 6 months~* Dosage of any concomitant medication has been stable for at least 3 weeks~* If female, postmenopausal (absence of menstruation for at least 12 months or absence of menstruation \> 6 months with FSH \> 40 ng/ml respectively oestrogen \< 20 pg/ml)~Exclusion Criteria:~* Subjects with additional causes for hyperlipoproteinemia~* Diabetes mellitus or antidiabetic medication~* Subject has history of cardiovascular ischemia in previous 3 months or acute myocardial infarction or unstable angina~* History of psychiatric disorder or cognitive impairment that would interfere with participation in the study~* History of alcoholism~* Contraindication against niacin and/or laropiprant~* Subject has participated in an investigational study within 30 days prior to study initiation~* Fasting triglycerides \>400 mg/dl~* Life-threatening disease (e.g. cancer)~* Renal insufficiency (GFR ≤ 30 ml/min )~* Major hepatic impairment~* Known allergic reaction/intolerance against niacin and/or laropiprant~* Active peptic ulcer disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Niacin/ Laropiprant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Histopathologically or cytologically confirmed, advanced or metastatic breast cancer (stage IIIb, IIIc or IV disease) including inflammatory breast cancer or inoperable locally advanced disease.~2. Documented ErbB2 overexpression~3. Estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors~4. Measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria~5. A life expectancy of \> 3 months for Phase 1 and \> 6 months for Phase 2~6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry in Phase 1 and ≤ 1 in Phase 2;~7. Normal cardiac ejection fraction~8. Adequate hematologic, hepatic and renal function~9. Post-menopausal female (defined as the absence of a menstrual cycle for at least 12 consecutive months) or male subjects ≥ 18 years of age.~10. Sign an IRB or EC approved informed consent~Exclusion Criteria~1. Type 1 diabetes or uncontrolled Type 2 diabetes~2. Subjects showing clinical evidence or with a history of cataract(s), proliferate retinopathy or significant macular edema~3. Subjects with abnormal free T4 values and a history or evidence of thyroid disease~4. Subjects who are unable or unwilling to take metformin~5. Uncontrolled intercurrent illness~6. Known or suspected human immunodeficiency virus (HIV) infection or hepatitis B or C~7. Subjects with inflammatory diseases of the gastrointestinal tract~8. History of other malignancy. Subjects who have been disease free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;~9. Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor~10. A history of prior treatment with other agents specifically targeting IGFRs~11. Subjects who require pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escallation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility